Abstract:The brainstems of diseased Ndufs4(−/−) mice—a mouse model of the genetic mitochondrial disease Leigh syndrome (LS)—have elevated levels of cytokines IP10 and IFNγ. To explore the role of these two factors in LS, we generated IFNγ and IP10 deficient Ndufs4(−/−) mice and evaluated survival and disease pathology. Loss of IP10 does not impact disease in Ndufs4(−/−) mice, but IFNγ loss prolongs survival and delays disease progression, indicating that IFNγ signaling contributes to disease onset and progression in LS. Aim Leigh syndrome (LS), the most common paediatric presentation of genetic mitochondrial dysfunction, is a multi‐system disorder characterised by severe neurologic and metabolic abnormalities. Symmetric, bilateral, progressive necrotizing lesions in the brainstem are defining features of the disease. Patients are often symptom free in early life but typically develop symptoms by about 2 years of age. The mechanisms underlying disease onset and progression in LS remain obscure. Recent studies have shown that the immune system causally drives disease in the Ndufs4(−/−) mouse model of LS: treatment of Ndufs4(−/−) mice with the macrophage‐depleting Csf1r inhibitor pexidartinib prevents disease. While the precise mechanisms leading to immune activation and immune factors involved in disease progression have not yet been determined, interferon‐gamma (IFNγ) and interferon gamma‐induced protein 10 (IP10) were found to be significantly elevated in Ndufs4(−/−) brainstem, implicating these factors in disease. Here, we aimed to explore the role of IFNγ and IP10 in LS. Methods To establish the role of IFNγ and IP10 in LS, we generated IFNγ and IP10 deficient Ndufs4(−/−)/Ifng(−/−) and Ndufs4(−/−)/IP10(−/−) double knockout animals, as well as IFNγ and IP10 heterozygous, Ndufs4(−/−)/Ifng(+/−) and Ndufs4(−/−)/IP10(+/−), animals. We monitored disease onset and progression to define the impact of heterozygous or homozygous loss of IFNγ and IP10 in LS. Results Loss of IP10 does not significantly impact the onset or progression of disease in the Ndufs4(−/−) model. IFNγ loss significantly extends survival and delays disease progression in a gene dosage‐dependent manner, though the benefits are modest compared to Csf1r inhibition. Conclusions IFNγ contributes to disease onset and progression in LS. Our findings suggest that IFNγ targeting therapies may provide some benefits in genetic mitochondrial disease, but targeting IFNγ alone would likely yield only modest benefits in LS.

Leukocytes mediate disease pathogenesis in the Ndufs4(KO) mouse model of Leigh syndrome

Peripheral macrophages causally contribute to disease onset and progression in the Ndufs4(KO) model of Leigh syndrome

Peripheral macrophages drive CNS disease in the Ndufs4(-/-) model of Leigh syndrome

IFNγ modestly contributes to disease progression in the Ndufs4(-/-) model of Leigh syndrome while IP10 is dispensable

Activated microglia and neuroinflammation as a pathogenic mechanism in Leigh syndrome

Interferon‐gamma contributes to disease progression in the Ndufs4(−/−) model of Leigh syndrome

Microglial response promotes neurodegeneration in the Ndufs4 KO mouse model of Leigh syndrome

Ndufs4 knockout mice with isolated complex I deficiency engage a futile adaptive brain response

The Blood–Brain Barrier Is Unaffected in the Ndufs4−/− Mouse Model of Leigh Syndrome

Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome

Defective metabolic programming impairs early neuronal morphogenesis in neural cultures and an organoid model of Leigh syndrome

Ndufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention

Disease models of Leigh syndrome: From yeast to organoids

Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity

Metabolic rescue ameliorates mitochondrial encephalo‐cardiomyopathy in murine and human iPSC models of Leigh syndrome

Mitochondria transfer-based therapies reduce the morbidity and mortality of Leigh syndrome

Leigh Syndrome: A Study of 209 Patients at the Beijing Children's Hospital

Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease

Mitochondrial Proteome of Affected Glutamatergic Neurons in a Mouse Model of Leigh Syndrome

Mitochondrial complex I deficiency leads to the retardation of early embryonic development in Ndufs4 knockout mice

Targeting NAD+ Metabolism as Interventions for Mitochondrial Disease